A report from Rodman & Renshaw reiterates its Market Outperform rating and $15 price target on ARIAD Pharmaceuticals ARIA.
The report states, “We believe ARIA shares are not fundamentally driven by earnings, therefore any EPS “beat” or “miss” is largely irrelevant. As a reminder,we expect ARIA to report FY 3Q11 EPS of $0.27 driven by receipt of a $25mm milestone payment in the quarter from Merck for the filing of ridaforolimus with the EMEA, as well as an estimated ~$35mm positive accounting effect from revaluation of existing warrants liability. Further, we forecast R&D and SG&A spend for the quarter to come in at $19.0mm and $6.4mm, respectively."
ARIA closed yesterday at $11.63.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in